Platelet-Rich Plasma in Knee Osteoarthritis: Clinical Insights for Orthopedic Practice

Knee osteoarthritis (KOA) is a progressive joint disorder marked by cartilage degeneration, subchondral bone remodeling, and synovial inflammation. With rising incidence due to aging and obesity, KOA presents a growing burden on healthcare systems. Standard care—including NSAIDs, physical therapy, corticosteroids, and eventually joint replacement—offers symptomatic relief but does not reverse the degenerative cascade.

Platelet-rich plasma (PRP) therapy has emerged as a regenerative intervention with the potential to address not just symptoms but disease-modifying pathways in KOA. This article examines the biological rationale, current clinical evidence, procedural guidance, and practical considerations for integrating PRP into orthopaedic management of knee osteoarthritis.

Pathophysiology of Knee Osteoarthritis

KOA is characterized by:

• Progressive cartilage loss
• Subchondral bone sclerosis
• Osteophyte formation
• Low-grade chronic synovitis

These structural and inflammatory changes result in pain, stiffness, reduced mobility, and functional limitation. Inflammatory mediators such as interleukin-1β (IL-1β), TNF-α, and matrix metalloproteinases (MMPs) play key roles in cartilage catabolism and joint degradation.

Standard Treatment Landscape

Initial management includes:

• Lifestyle modification (weight loss, activity adjustment)
• Physical therapy to improve strength and joint mechanics
• NSAIDs and acetaminophen for pain control
• Intra-articular corticosteroids or hyaluronic acid (HA) injections for temporary relief
• Surgical options (e.g., total knee arthroplasty) for advanced disease

While these therapies may provide short-term symptom relief, none directly promote cartilage repair or halt disease progression.

Biological Rationale for PRP in KOA

PRP is an autologous plasma concentrate enriched with platelets. Upon activation, platelets release key growth factors and cytokines such as:

• Transforming growth factor-beta (TGF-β)
• Platelet-derived growth factor (PDGF)
• Vascular endothelial growth factor (VEGF)
• Insulin-like growth factor-1 (IGF-1)

These factors modulate inflammation, stimulate chondrocyte proliferation, enhance matrix synthesis, and improve tissue homeostasis.

In KOA, PRP is believed to:

• Reduce synovial inflammation
• Modulate nociceptive pathways
• Improve lubrication
• Stimulate endogenous repair of cartilage microdefects

Evidence Supporting PRP in Knee Osteoarthritis

Randomized Controlled Trials (RCTs)

Numerous RCTs demonstrate PRP’s superiority over saline, corticosteroids, and HA in reducing pain and improving function in KOA:

• Patel et al. (2013): PRP resulted in significant improvement in WOMAC scores compared to saline at 6 months.
• Shen et al. (2017): PRP outperformed HA in patients with early to moderate KOA.
• Khoshbin et al. (2013): Meta-analysis showed PRP was more effective than HA for symptom relief up to 12 months.

Systematic Reviews and Guidelines

• A 2021 AAOS clinical practice guideline gives a “limited” recommendation for PRP in KOA due to variability in formulations and protocols—but notes it may be reasonable in selected patients.
• The Osteoarthritis Research Society International (OARSI) considers PRP promising but calls for standardization and long-term data.

However, variations in PRP preparation, injection protocols, and outcome measures remain a challenge in standardizing recommendations.

Preparation and Injection Protocols

PRP Formulations

There is no universal PRP preparation. Most systems yield either:

• Leukocyte-rich PRP (LR-PRP): May provoke more inflammation; considered suitable for tendinopathies.
• Leukocyte-poor PRP (LP-PRP): Preferred for intra-articular use due to reduced pro-inflammatory cytokines.

For KOA, LP-PRP is generally favored.

Injection Technique

• Image Guidance: Ultrasound or fluoroscopy improves accuracy, especially in obese or anatomically challenging patients.
• Volume: Typically, 5–8 mL of PRP is injected intra-articularly.
• Frequency: Most studies support 2–3 injections spaced 1–3 weeks apart.

Post-Injection Recommendations

• Rest for 24–48 hours
• Avoid NSAIDs for at least one week
• Gradual return to activity with structured physical therapy

Patient Selection and Clinical Considerations

Ideal Candidates

• Mild to moderate KOA (Kellgren-Lawrence grade II–III)
• Refractory to conservative therapy
• Not ready or eligible for surgery

Contraindications

• Active infection
• Bleeding disorders or anticoagulation
• Advanced bone-on-bone osteoarthritis (grade IV)
• Inflammatory arthropathies

Safety Profile

PRP is autologous and well-tolerated. Minor adverse effects include injection-site discomfort, swelling, or stiffness. Serious complications are rare.

Limitations and Future Directions

Despite promising data, PRP therapy faces several challenges:

• Lack of standardization in PRP concentration, leukocyte content, and activation methods
• Inconsistent dosing protocols across trials
• Variable insurance coverage and out-of-pocket costs for patients

Future priorities include:

• Developing consensus preparation guidelines
• Identifying biomarkers to predict treatment response
• Comparing PRP with emerging orthobiologics such as BMAC (bone marrow aspirate concentrate) or MSCs (mesenchymal stem cells)

Conclusion

PRP offers a biologically active, minimally invasive therapy for knee osteoarthritis that may slow progression and improve symptoms, especially in early to moderate disease stages. While not a cure, PRP holds clinical value as a safe, repeatable option that can delay the need for surgery in select patients.

Orthopaedic clinicians should consider patient selection, PRP formulation, and procedural precision when integrating PRP into practice. As research evolves, PRP is likely to become a more standardized and accessible tool in the treatment arsenal for degenerative joint disease.

References

1. Patel S, et al. (2013). Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med; 41(2):356–64.
2. Shen L, et al. (2017). Intra-articular platelet-rich plasma vs. hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis. Am J Phys Med Rehabil; 96(5): 319–25.
3. Khoshbin A, et al. (2013). The efficacy of platelet-rich plasma in the treatment of symptomatic knee osteoarthritis: a systematic review with quantitative synthesis. Arthroscopy; 29(12):2037–48.
4. American Academy of Orthopaedic Surgeons (AAOS). (2021). Clinical Practice Guidelines: Management of Osteoarthritis of the Knee (Nonarthroplasty). www.aaos.org
5. Osteoarthritis Research Society International (OARSI). (2019). OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. www.oarsi.org
6. RegenOMedix. (2024). PRP Therapy Overview. https://regenomedix.com/prp-therapy
7. Filardo G, et al. (2012). Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc; 20(10):2094–101.